乳腺癌前哨淋巴结活检分期的术者相关差异
该研究基于SEER-Medicare数据库2007-2011年接受乳腺癌手术的15571例患者(对应2478名术者),分析术者间前哨淋巴结切除数量及肿瘤学阳性检出率的差异。结果显示,各T分期下术者间切除淋巴结数量及阳性检出率均存在显著差异(P < .001),提示需标准化手术实践以优化分期准确性。
要点
- 不同术者切除的前哨淋巴结数量在各T分期均存在显著差异(P < .001)。
- 术者间前哨淋巴结阳性检出率在各T分期也存在显著差异(P < .001)。
- 术者年均前哨淋巴结手术量差异大(1.3例,范围1-103),提示需标准化实践。
核心结论
- 乳腺癌腋窝前哨淋巴结分期存在术者相关差异,提示需改进手术标准化以优化肿瘤学检出并确保准确分期。
研究设计与样本
- 回顾性队列研究,纳入SEER-Medicare数据库2007-2011年接受乳腺癌手术的15571例患者,对应2478名术者。
- 采用线性混合效应回归和逻辑混合效应回归模型分析术者间差异。
主要发现
- 术者年均前哨淋巴结手术量为1.3例(范围1-103),最低四分位术者每年≤1例,最高四分位术者每年>8例。
- 各T分期下,术者间切除的前哨淋巴结数量存在显著差异(P < .001)。
- 各T分期下,术者间前哨淋巴结阳性检出率存在显著差异(P < .001)。
- 所有术者切除的前哨淋巴结平均数量随T分期增加而增加(P < .001),N0患者(P < .001)和淋巴结阳性患者(P = .003)分别评估时亦然。
临床怎么用
- 普通外科智能体应提醒术者关注前哨淋巴结切除数量与阳性检出率的标准化,避免过度切除或分期不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sentinel lymph node biopsy is the gold standard for axillary staging in early-stage, clinically node-negative breast cancer, so it is paramount that this operation be both precise and accurate, because excessive sentinel lymph node removal increases morbidity, whereas understaging risks inadequate treatment. The goal of this study was to assess surgeon variation in the number of sentinel lymph nodes removed and the oncologic yield of sentinel lymph node biopsy for breast cancer. METHODS: All patients in the Surveillance, Epidemiology, and End Results-Medicare database who underwent operative treatment for breast cancer from 2007-2011 were eligible for inclusion. Deidentified provider codes were used to track operations performed by individual surgeons. Only records in which an individual surgeon could be linked to a specific breast cancer operation were analyzed. The total number of sentinel lymph nodes removed and the number that were pathologically positive (oncologic yield) were recorded. Surgeon variation by T stage was analyzed using linear mixed-effects regression and logistic mixed-effects regression models. RESULTS: Query of the database identified 15,571 patients who met inclusion criteria, representing 2,478 providers. The mean number of sentinel lymph node procedures performed per provider per year was 1.3 (range 1-103). The lowest quartile of providers performed 1 or fewer sentinel lymph node procedures per year. The highest quartile of providers performed >8 sentinel lymph node procedures per year. The average number of sentinel lymph node removed per operation increased with increasing T stage for all providers (P < .001), including when N0 (P < .001) and node-positive (P = .003) patients were evaluated separately. There was surgeon-associated variation in the number of sentinel lymph node removed for each T stage (P < .001). In addition, there was surgeon-associated variation in the oncologic yield (sentinel lymph node positivity rate) by T stage (P < .001). CONCLUSION: This study found surgeon-associated variation in axillary sentinel lymph node staging of breast cancer patients, which suggests the need to improve standardization of surgical practices to optimize the oncologic yield of these procedures and ensure accurate staging.
引用
- Larson KE, Valente SA, Tu C, et al. Surgeon-associated variation in breast cancer staging with sentinel node biopsy. Surgery. 2018. PMID: 30093273. doi:10.1016/j.surg.2018.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。